Company intelligence / Profile preview

Meatable

Delft, South Holland, Netherlandsmeatable.com ↗

Ownership: Private
Development stage: Other

Overview

Meatable has demonstrated successful production of cultivated pork sausages using its proprietary opti‑ox™ stem cell platform. The company was the first to receive EU regulatory approval for public tasting of cultured meat in April 2024. Production times have been reduced from three weeks to eight days, with ongoing scale-up efforts. No clinical results as it does not develop therapeutics.

Therapeutic areas: Other
Modalities: Induced pluripotent stem cell derived therapyCell therapy
Industry: Non-Drug Biotech

Partnerships

Royal DSM (joint development agreement)ESCO Aster (manufacturing partnership in Singapore)Love Handle (hybrid product collaboration in Singapore)

Beyond the preview

Go deeper on Meatable.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meatable.

Explore the full profile